• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of new bio-therapy with chimeric peptide target tumor cell surface molecules of oral cancer

Research Project

Project/Area Number 24390449
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypePartial Multi-year Fund
Section一般
Research Field Surgical dentistry
Research InstitutionUniversity of Tsukuba

Principal Investigator

BUKAWA HIROKI  筑波大学, 医学医療系, 教授 (80173558)

Co-Investigator(Kenkyū-buntansha) SHODA Junichi  筑波大学, 医学医療系, 教授 (90241827)
KAWAKAMI Koji  京都大学, 大学院医学研究科, 教授 (70422318)
Project Period (FY) 2012-04-01 – 2015-03-31
Project Status Completed (Fiscal Year 2014)
Budget Amount *help
¥18,200,000 (Direct Cost: ¥14,000,000、Indirect Cost: ¥4,200,000)
Fiscal Year 2014: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2012: ¥9,230,000 (Direct Cost: ¥7,100,000、Indirect Cost: ¥2,130,000)
Keywordsキメラペプチド / IL-4R / 口腔がん / 臨床腫瘍学
Outline of Final Research Achievements

Interleukin-4 receptor α (IL-4Rα) is highly expressed on the surface of oral squamous cell carcinoma (OSCC). We designed a novel IL-4Rα-lytic hybrid peptide composed of a binding peptide to IL-4Rα and a cell-lytic peptide. We evaluated the antitumor activity of the IL-4Rα-lytic hybrid peptide as a novel molecular-targeted therapy in OSCC. Immunoblot analysis revealed that IL-4Rα was expressed in all tested OSCC cell lines, but not in a human normal keratinocyte (HaCaT) cell line. Immunohistochemical expression levels of IL-4Rα in OSCC tissues were higher compared to those in normal epithelial tissue. The IL-4Rα-lytic hybrid peptide showed cytotoxic activity in cancer cell lines with a concentration that killed 50% of all cells (IC50) as low as 10uM. HaCaT cells were less sensitive to this peptide with an IC50 of >30uM. In addition, intratumoral administration of IL-4Rα-lytic hybrid peptide significantly inhibited tumor growth in a xenograft model of human OSCC in vivo.

Report

(4 results)
  • 2014 Annual Research Report   Final Research Report ( PDF )
  • 2013 Annual Research Report
  • 2012 Annual Research Report
  • Research Products

    (2 results)

All 2013 2012

All Journal Article (1 results) (of which Peer Reviewed: 1 results) Presentation (1 results)

  • [Journal Article] Interleukin-4 receptor α-based hybrid peptide effectively induces antitumor activity in head and neck squamous cell carcinoma.2013

    • Author(s)
      Kaori Seto
    • Journal Title

      Oncology Report

      Volume: xx Issue: 6 Pages: 2147-2153

    • DOI

      10.3892/or.2013.2387

    • Related Report
      2012 Annual Research Report
    • Peer Reviewed
  • [Presentation] 口腔がんに対するインターロイキン4受容体を標的とした新しい分子標的治療の開発2012

    • Author(s)
      瀬戸佳穂里
    • Organizer
      第57回 日本口腔外科学会総会
    • Place of Presentation
      パシフィコ横浜
    • Year and Date
      2012-10-19
    • Related Report
      2012 Annual Research Report

URL: 

Published: 2012-04-24   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi